PRIMA BIOMED

Australian biotechnology company Prima BioMed Ltd is one of the world's leaders when it comes to cancer treatment. We focus on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. Scientific research, product development and clinical trials are the essentials of what we call the cutting edge of the fight against cancer.

Product Development The company has 2 programs in place. The lead program, CVac™ has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer. >>	Scientific Research Prima BioMed's technologies all result from research on the human immune system. In summary, the technology platforms behind the Product Pipeline are: Dendritic cell therapy, Monoclonal Antibodies. >>	Clinical Trial CVac™ cell therapy is a new and groundbreaking technology for the treatment of cancer. It stimulates the production of immune cells, produced naturally in the body, that attack cancer cells. >>	Latest News 23 May 2013 Ä̈rzteblatt Sachsen: Die Autologe Immuntherapie des Ovarialkarzinoms – Eine neue Chance? // Autologous immunotherapy forovarian carcinoma – A new chance? >> 20 May 2013 Prima BioMed to present at the Second Annual Marcum LLP MicroCap Conference >> 17 May 2013 Cleansing Statement & Appendix 3B /Mittelzufluss aus Aktienplatzierung in Höhe von 6,2 Mio. AUD >> Read more news >> Press and Video Webcast (Apr 2013) >> Webcast (Mar 2013) >> Webcast (Feb 2013) >> Manufacturing of CVac >> Interview Marc Voigt (D) >> Interview Matt Lehman >> Movie about CVac™ >> Channel 7 News >> Channel 10 News >> Channel 7 News >> Webcast (Nov 2012) >>
Connect with Prima Receive email updates and follow us on Facebook, Twitter and on LinkedIn: